The occurrence of opportunistic infections is an established complication in patients diagnosed with systemic lupus erythematosus (SLE). The foremost challenge in such circumstances is differentiating between an exacerbation or progression of SLE, and the effects of the infection itself.1 Toxoplasma gondii is a ubiquitous parasite that often causes an asymptomatic infection in healthy, immunocompetent adults….
It is with great sadness that we report the passing of a giant of international rheumatology, Professor Shunle Chen. He was a friend, colleague, collaborator, visionary leader and inspiration to many rheumatologists in China and the world. Moreover, despite his interÂnational stature, he was a warm friend and nurturing mentor to all those who had…
Just YouTube it. As a rheumatologist who sees many patients with granulomatosis with polyangiitis (GPA), I have spent a significant portion of my life talking to people about neti pots. Originally, the neti pot was part of the Ayurvedic tradition. Neti pots were used to flush the sinuses with water, milk and ghee, or to…
In Canada, a subcutaneous formulation of CT-P13, which is biosimilar to infliximab, was approved to treat rheumatoid arthritis.
Research from Ellingwood et al. examines how often patients diagnosed with early RA experience episodic joint inflammation and describes characteristics that may result in RA development.
Experts at ACR Convergence 2020 addressed how diet & the body’s microbiome affect chronic diseases.
Camelot allegedly existed once upon a time in South Wales. The name was evoked again in the 1960s, but perhaps it is also applicable to the character of rheumaÂtology in the halcyon days of the 1970s and 80s. That’s not to belittle the world we now live in, with so many treatment options for our…
Sapart et al. suggest a combination of methotrexate and biologic disease-modifying anti-rheumatic drugs as induction therapy for patients with early RA may lead to long-term remission.
In a post-marketing safety study, tofacitinib did not prove non-inferior to tumor necrosis factor inhibitors when evaluated for its long-term effects on heart disease, malignancies and serious infections in RA patients.
In January, upadacitinib was approved for use in Europe as a 15 mg, once-daily dose to treat patients with psoriatic arthritis and ankylosing spondylitis.